Aptevo Therapeutics And MorphoSys AG End Joint Development And Commercialization Agreement For MOR209/ES414
Published: Sep 01, 2017
Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414
Preliminary Phase I Data Show Markedly Lower Anti-Drug Antibody Titers Demonstrating Effectiveness of New Dosing Regimen
SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced the end of its partnership with MorphoSys AG for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic for the treatment of metastatic castration resistant prostate cancer (mCRPC). Aptevo will regain worldwide development and commercialization rights for MOR209/ES414 (now known as APVO414) and intends to continue to advance APVO414 through the completion of Stage 1 of an ongoing Phase 1 continuous infusion, dose-escalation clinical study evaluating the safety, tolerability and clinical activity of escalating doses of APVO414 in patients with mCRPC.
“We’re encouraged by the latest preliminary data from the ongoing Phase 1 clinical study of APVO414,” said Dr. Scott Stromatt, Senior Vice President and Chief Medical Officer at Aptevo. “The data suggest that administration of APVO414 by continuous infusion, rather than weekly intravenous (IV) dosing, is effective at reducing the titer of anti-drug antibodies (ADA) previously observed in the initial weekly IV dosing cohorts.”
In the initial cohorts of the Phase 1 dose escalation study, twelve patients with mCRPC were treated with weekly intravenous infusions of APVO414. Seven of these patients (58%) developed ADA with very high titers (as high as 1:250,000). None of the patients had any adverse reactions due to the ADA, but patients with high ADA titers cleared the drug from their blood to undetectable levels.
The amended protocol utilizes continuous intravenous infusion and two cohorts of patients have completed dosing without any dose limiting toxicities. Three of six patients (50%) developed ADA but with markedly lower titers of ADA (1:160 or 1:320). Additionally, drug was detected in the serum of all patients.
“These results clearly demonstrate that the administration regimen markedly reduced the generation of ADA. Additionally, we have seen early pharmacodynamic effects of the drug such as redistribution of T cells. We are encouraged and plan to continue dose escalation in order to determine the maximum tolerated dose and to examine the clinical activity of APVO414,” said Dr. Stromatt.
APVO414 is a first-generation bispecific antibody candidate, developed using Aptevo’s ADAPTIR™ protein therapeutic platform. APVO414 is engineered to simultaneously target PSMA on prostate cancer cells, and CD3 on T-cells, and functions by redirecting cytotoxic T cell activity towards PSMA-expressing tumor cells.
Promising preclinical data demonstrating the ability of APVO414 to induce target-dependent tumor cell killing as well as target-dependent T cell proliferation were previously presented at the American Association for Cancer Research Annual Meeting and recently published in the Journal of Molecular and Cellular Biology (2016 Mol Cancer Ther; 15(9); 2155–65). In addition, APVO414 demonstrated lower levels of T cell dependent cytokines compared to other bispecific formats, which, if confirmed in clinical studies, could offer the potential for enhanced safety and tolerability compared to other immuno-oncology bispecific antibody approaches.
“Aptevo has made a number of significant improvements to our ADAPTIR platform since the development of our first-generation bispecific candidates, like APVO414,” commented Jane Gross, Ph.D., Senior Vice President and Chief Scientific Officer. “Our next generation ADAPTIR technology platform has been optimized to enable the development of bispecific antibody candidates with highly-desirable drug-like properties, including, enhanced potency and stability, prolonged half-life, and excellent manufacturing attributes – similar to traditional antibodies. Importantly, we have utilized state-of-the-art technologies to examine our next generation bispecific candidates and believe that we identified and eliminated the root cause of the ADA seen with APVO414. We look forward to obtaining additional information from the ongoing APVO414 clinical trial and advancing next generation ADAPTIR bispecific molecules into clinical development.”
About Prostate Cancer
Although screening, radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early-stage prostate cancer, the relapse rate following initial anti-androgen therapy remains high, and there remains a significant unmet medical need for patients with metastatic castration resistant prostate cancer for whom current therapies have demonstrated only a limited increase in overall survival. The global market for CRPC therapeutics is expected to reach $9.5 billion by 2020
About the ADAPTIR Pipeline
Two first generation ADAPTIR molecules are currently in clinical development: APVO414, which is being investigated in a Phase 1, dose escalation, continuous infusion study to evaluate safety and tolerability in patients with metastatic castration resistant prostate cancer; and, otlertuzumab, a monospecific antibody targeting CD37 under investigation for the treatment of chronic lymphocytic leukemia. In addition, Aptevo has several ADAPTIR candidates in preclinical development, including: APVO436, an optimized, next generation bispecific antibody candidate designed to simultaneously target CD123 and CD3 and redirect T cell cytotoxicity for the treatment of acute myelogenous leukemia (AML), a form of blood and bone marrow cancer; ALG.APV-526, a bispecific antibody candidate, partnered with Alligator Bioscience, featuring a novel mechanism of action designed to simultaneously target 4-1BB (CD137) and an undisclosed tumor antigen, and, APVO210 – a bispecific ADAPTIR candidate with a novel mechanism of action based on cytokine delivery currently in preclinical development for autoimmune and inflammatory diseases.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. The Company has four commercial products – IXINITY®, WinRho® SDF, HepaGam B® and VARIZIG® and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated, bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases. Aptevo has two bispecific antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease/inflammation. For more information, please visit www.aptevotherapeutics.com
Aptevo Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook, financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, Aptevo’s future growth rates, Aptevo’s ability to timely manufacture its products, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers to supply product and materials; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets and our ability to retain patients; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Annual Report on Form 10-K, as filed on March 31, 2017, and our subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications Tel: +1 206-859-6628 JurchisonS@apvo.com